GOOD NEWS FOR SMITHKLINE BEECHAM: On May 26, an advisory panel of the Food & Drug Administration recommended that the agency approve SmithKline's vaccine for Lyme disease. But the committee urged SmithKline to continue testing, raising concerns about the extent of the study as well as the possibility that diagnosing the disease would be more difficult in patients who had received the vaccine. The vaccine, designed using new gene technology, must now be approved by the FDA, which usually follows the recommendations of its panels.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE